Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

A U.S. federal judge approves a deal between Novo Nordisk (NVO) and Minnesota that settled a lawsuit over high insulin prices ...

March 24 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... 2025 Healthcare & Pharmaceuticalscategory US FDA greenlights GSK's drug for UTIs in women and girls March 25, 2025 Anduril ...

In the US, Wegovy is priced at about ... companies like Hims & Hers Health Inc., which offer the drugs through a monthly subscription model Novo Nordisk shares were up about 3% at 4:40 p.m ...

Novo Nordisk is reorganizing its research and early development unit in an effort to “future-proof the organization” and ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance ...

The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...

U.S. Operations and Global Business Development and President of Novo Nordisk Inc. "With the evolution of our Wegovy® savings program, we continue to deliver options that empower people living ...

The McGill University Health Centre (MUHC) Foundation is proud to announce a $2 million donation from Novo Nordisk Canada Inc. to support the establishment of the Metabolic Centre of Excellence at the ...